Blood test may spot Alzheimer's early?
NCT ID NCT00647478
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study measured levels of two substances (IGF-I and IGFBP-3) in the blood of 693 older adults: some with Alzheimer's disease, some with mild cognitive impairment, and some with normal memory. The goal was to see if these levels differ between groups and relate to thinking abilities. It is an observational study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify biological markers for early detection or progression of Alzheimer's disease.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures substances in the blood, so it cannot prove cause or lead directly to a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Broca Hospital Memory Clinic (CMRR)
Paris, Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Refresher training may extend brain benefits for veterans with mild memory issues